A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.
David Paul Morris | Bloomberg | Getty Images
Now is a good entry point into Gilead’s stock as the company begins to stabilize, while still trading at a discount to its peers, according to RBC Capital Markets.
The firm named biotechnology company Gilead to its top picks list and maintained its $91 price target, a near 34% upside.
This article was originally published by Cnbc.com. Read the original article here.